TheEdgeResearch
Home / Stocks / AKAN

Akanda Corp. (AKAN)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$5.33 ▲ +2.30%
Market Cap
$172,511
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
1.73
52-Wk Range
2.2973-209.23424
CEO
Katharyn Field
Country
GB
Currency
USD

Akanda Corp. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in New Romney, KE, GB. The stock last traded at $5.33, up 2.30% on the session, giving a market capitalisation of $172,511. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -17658.5%. Its beta of 1.73 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.01
Price / Sales
0.67
Price / Book
-0.03
EV / EBITDA
-2.86
Gross margin
-382.7%
Operating margin
-2022.7%
Net margin
-17658.5%
Return on equity
Debt / equity
-1.32
Current ratio
0.58
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
8
IPO date
2022-03-15
Headquarters
New Romney, KE, GB
About Akanda Corp.

Akanda Corp., operating through its various subsidiary entities, focuses on the cultivation, production, and distribution of cannabis products. The company's operations span the United Kingdom, Lesotho, and other global regions, with a specific aim to provide cannabis-derived items for medical and wellness purposes. Formed in 2021, Akanda Corp. is based out of its main office in New Romney, United Kingdom.

Comparable companies

Akanda Corp. is most often compared with the following Healthcare names:

BBLGGCTKGNPXHSCSIMCCJAGXPRFXRDHLSHPHUPC
More research on AKAN
AKAN technical analysis AKAN TheEdge Score Compare against peers
Open full interactive analysis & DCF →